逼近1600元！寒武纪涨超15%再创新高，超越贵州茅台稳居A股“股王”宝座，市值升破6600亿，本月累涨涨幅123%，2023年至今累计涨幅超2800%

Group 1 - The core viewpoint of the article highlights the significant stock performance of Cambrian Biologics (寒武纪-U), which saw its share price rise over 16% to reach a historical high of 1595.88 yuan, ultimately closing at 1587.91 yuan, with a market capitalization of 664.3 billion yuan [1][3] - Cambrian Biologics has experienced a remarkable cumulative increase of 123% in August and over 2800% year-to-date in 2023 [1] Group 2 - The company reported its semi-annual results on August 26, revealing a revenue of 2.881 billion yuan for the first half of 2025, representing a year-on-year growth of 4347.82% [3] - The net profit for the same period was 1.038 billion yuan, a significant turnaround from a loss of 530 million yuan in the previous year [3]